RAFARM S.A.
↗Paiania, Greece
RAFARM is a leading innovation-driven Greek pharmaceutical company and a significant European CDMO specializing in complex ophthalmic and injectable products. Founded in 1974, the company has evolved from a local distributor into a global player, exporting to over 60 countries and maintaining a strong presence in the US and European markets.
The company is recognized for its state-of-the-art R&D capabilities, centered at its 'Atheia' R&D Center, and its high-tech manufacturing facilities. RAFARM focuses on the development and production of complex generics and value-added medicines (VAMs), offering end-to-end CDMO services from laboratory scale to commercial production.
CLASSIFICATION
Company Type:CDMO
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Ophthalmology and Sterile Injectables
SIZE & FINANCIALS
Employees:501-1000
Revenue:$100M-$500M
Founded:1974
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Sterile injectables, Ophthalmic solutions, Ophthalmic suspensions, Ophthalmic emulsions
Active Trials:0
Trial Phases:-
FDA Approvals:8
EMA Approvals:50
CORPORATE STRUCTURE
Key Partnerships:Cliantha (India) - Clinical research, University of Michigan (USA) - R&D collaboration, Bausch + Lomb - Distribution and licensing, MRC Systems - Manufacturing infrastructure
COMPETITION
Position:Leader
Competitors:Demo S.A., Elpen Pharmaceutical, Pharmathen, Faran S.A.
LEADERSHIP
Key Executives:
Aris Mitsopoulos - Vice President
George Chalkias - Chief Scientific Officer
Maria Demetre - Head of Business Development
Board Members:Eirini Rassia (Executive VP), Ioanna Rassia (Executive VP)
LINKS
Website:rafarm.gr
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with RAFARM S.A.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.